In its new evidence-based clinical practice guideline, the Endocrine Society recommends against routine 25(OH)D testing in the absence of indications and limiting vitamin D supplementation.
In a new data analysis, Harvard researchers find that insulin manufacturers have filed multiple patents on delivery devices following the original insulin product approval.
Study findings suggest that patients be screened for vitamin D deficiency before starting SGLT2 inhibitor therapy, or they should simply be prescribed vitamin D supplements.
Researchers propose the use of ratios of vitamin D metabolites that take into account individual differences in vitamin D binding proteins to improve prediction of secondary hyperparathyroidism risk.
Study provides real-world assurance that SGLT2 inhibitors have no added risk of fracture in patients with mainly mild kidney disease after a year of use. But follow-up was short, say experts.